Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Old ingredient database

This article was originally published in The Tan Sheet

Executive Summary

The American Herbal Products Association is asking its members and other manufacturers to submit records on "old dietary ingredients" (ODIs) that were marketed prior to Oct. 15, 1994. President Michael McGuffin said AHPA wants to put together the database so manufacturers can know "once and for all" if an ingredient needs a New Dietary Ingredient (NDI) notification. The company specifically is soliciting pre-1994 printed records, such as labels, product catalogues, invoices, packing lists, certificates of analysis, product specification sheets, and production or packaging records, which document the marketing or sale of individual dietary ingredients or their presence in a company's product line. AHPA intends to use this information to create a centralized "ODI Substantiation Database"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel